The consultant may support some or all of the following, based on experience and the company's priorities:
Regulatory strategy input for programs moving from Phase II toward Phase III and registration
Preparation of FDA and EMA meeting packages, including briefing documents for End of Phase II, Type B and Type C meetings
Authoring and review of IND amendments, annual reports, expedited pathway requests and other submissions
BLA readiness activities, such as gap analyses, submission planning and Module 2 content review
Health authority question responses and correspondence
Regulatory intelligence and precedent research for oncology and autoimmune biologics
Ad hoc strategic advice to the regulatory leader and program teams
Required Qualifications
10+ years of regulatory affairs experience in biotech, pharma or a regulatory consultancy
Experience supporting clinical stage programs, with exposure to late stage development and FDA meetings
Strong regulatory writing skills, including briefing documents and submission content
Experience with biologics or large molecule therapeutics
Comfort working independently and flexibly within a lean biotech team
Availability for a consistent part time commitment
Preferred Qualifications
Phase III, BLA or launch experience
Oncology, hematology or autoimmune therapeutic area experience
Experience with antibodies, bispecifics or cell depleting therapies
EMA and global regulatory experience
Prior FDA experience or a background in a regulatory consultancy